Disease modification in osteoarthritis; pathways to drug approval

Jeffrey N.Katz, TuhinaNeogi, Leigh F.Callahan, Joel A.Block, Philip G.Conaghan, Lee S.Simon, Virginia Byers Kraus, Marc C.Hochberg

https://www.sciencedirect.com/science/article/pii/S2665913120300480

Summary

Objective

To summarize proceedings of a workshop convened to discuss advances in disease modifying osteoarthritis (OA) drugs and regulatory challenges in bringing these drugs to market.

Design

Summary of a one-day workshop held in Washington, DC in May 2019.

Results

Attendees presented data documenting the prevalence, cost and disability burden of OA; recent documentation of disease modification without concomitant clinical benefit in trials of disease modifying drugs; regulatory considerations pertinent to disease modifying therapy; and methodologic approaches to addressing these regulatory considerations.

Conclusions

The research, pharmaceutical and regulatory communities must continue to collaborate on defining pathways for approval of disease modifying osteoarthritis drugs that document effects on clinical endpoints (such as pain, function or joint replacement) as well as on bone, cartilage and other structures.

Return to news section